Verastem (NASDAQ:VSTM – Free Report) had its target price lowered by Truist Financial from $18.00 to $15.00 in a research note published on Tuesday, Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research firms have also issued reports on VSTM. HC Wainwright reduced their price target on shares of Verastem from $17.50 to $7.00 and set a buy rating for the company in a research report on Monday, August 12th. B. Riley reduced their price target on shares of Verastem from $21.00 to $7.00 and set a buy rating for the company in a research report on Wednesday, July 24th. Alliance Global Partners dropped their price objective on shares of Verastem from $34.00 to $20.00 and set a buy rating on the stock in a research note on Wednesday, May 29th. Royal Bank of Canada dropped their price objective on shares of Verastem from $16.00 to $13.00 and set an outperform rating on the stock in a research note on Friday, August 9th. Finally, StockNews.com raised shares of Verastem from a sell rating to a hold rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $17.86.
View Our Latest Stock Report on Verastem
Verastem Stock Performance
Verastem (NASDAQ:VSTM – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.75. The business had revenue of $10.00 million for the quarter. On average, analysts anticipate that Verastem will post -3.95 EPS for the current year.
Institutional Investors Weigh In On Verastem
A number of institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new stake in Verastem in the 2nd quarter valued at $82,000. Rhumbline Advisers grew its stake in Verastem by 4,172.0% in the 2nd quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 28,119 shares during the period. Bank of New York Mellon Corp acquired a new stake in Verastem in the 2nd quarter valued at $203,000. Vanguard Group Inc. grew its stake in Verastem by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,160,931 shares of the biopharmaceutical company’s stock valued at $13,699,000 after acquiring an additional 10,678 shares during the period. Finally, Cannon Global Investment Management LLC acquired a new stake in Verastem during the 1st quarter worth $131,000. Institutional investors and hedge funds own 88.37% of the company’s stock.
Verastem Company Profile
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Featured Stories
- Five stocks we like better than Verastem
- Why is the Ex-Dividend Date Significant to Investors?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- Technology Stocks Explained: Here’s What to Know About Tech
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Market Cap Calculator: How to Calculate Market Cap
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.